๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca231 Eli Lilly and Company150 AbbVie142 Merck Sharp & Dohme LLC129 Novartis Pharmaceuticals113
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in California

5301 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults โ‰ฅ50 Years With Immunobridging to Adults 18-49
NCT07284654Pneumococcal Vaccines
Drugs31-valent pneumococcal conjugate vaccine·Capvaxive·PCV20
Vaxcyte, Inc.
Phase 3
4,049
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2025-12-01
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Recruiting
Safety and Usability of the Cionic Neural Sleeve for Parkinson's Disease
NCT07284823Parkinson Disease (PD)
Cionic, Inc.
Not applicable
10
California
2025-12
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Maryland
2025-11-30
Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484Type 2 Diabetes, Cortisol Excess
DrugClofutriben
Sparrow Pharmaceuticals
Phase 2
1,500
Arizona, California, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2025-11-29
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
NCT07144852Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
260
Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Minnesota
2025-11-29
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
DrugRina-S
Genmab
Phase 3
660
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-11-28
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naรฏve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsCabazitaxel·Xaluritamig·Abiraterone acetate·Paclitaxel
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Alabama, Arizona, California, Florida, Indiana, Michigan, Minnesota, Nebraska
2025-11-27
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
NCT06994845Primary Immunoglobulin A Nephropathy (IgAN)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
31
California, Colorado, Florida, Pennsylvania, Utah
2025-11-27
Recruiting
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625Acromegaly
Debiopharm International SA
Phase 3
119
California, Illinois, Massachusetts, Missouri, Nevada, New York, Ohio, Oregon
2025-11-26
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Recruiting
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
NCT07233239Focal Seizures
DrugCbd-Os
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
Recruiting
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Active, closed
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
NCT07266558SARS-CoV-2
DrugsMRNA-1273·MRNA-1283
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
By invitation
Observational Study of VYKATโ„ข XR in Patients With Prader-Willi Syndrome
NCT07450664Prader-Willi Syndrome
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-11-26
By invitation
Tracking Self-Reported Functional Needs and Quality of Life
NCT07284810Upper Motor Neuron Disease
Cionic, Inc.
Not applicable
1,000
California
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Arkansas, California, Florida, Texas
2025-11-26
Recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 3
468
Arizona, California, Louisiana
2025-11-25
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Recruiting
A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.
NCT07225751Ankle Arthrodesis or Arthroplasty, Hindfoot Fusion, Ankle Deformity, Ankle Disease
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
Recruiting
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
NCT07142291Amyotrophic Lateral Sclerosis (ALS)
DrugsCromolyn Sodium·Riluzole
PhenoNet, Inc.
Phase 2
105
Arizona, California, Florida, New York
2025-11-25
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOYยฎ (US-Sourced YERVOYยฎ) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650Hepatocellular Carcinoma (HCC)
DrugsYervoy·Opdivo
Shanghai Henlius Biotech
Phase 1
246
California, Florida, Tennessee, Texas, Washington
2025-11-25
Recruiting
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
NCT07209397Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
InMode MD Ltd.
Not applicable
202
California, District of Columbia, Idaho, Illinois, Kansas, Massachusetts, Nebraska, Nevada
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
NCT07213778Symptomatic Venous Thromboembolism (VTE)
DrugCenvacibart
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Active, closed
Taldefgrobep Alfa in Adults With Overweight and Obesity
NCT07281495Obesity, Overweight
DrugTaldefgrobep alfa
Biohaven Therapeutics Ltd.
Phase 2
150
California, Florida, Illinois, Indiana, Louisiana, Missouri, North Carolina, North Dakota
2025-11-24
Active, closed
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
NCT07232004Healthy Volunteer
AbbVie
Phase 1
121
Alabama, Arkansas, California, Florida, Illinois, Massachusetts, Minnesota, Missouri
2025-11-24
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Active, closed
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015Atopic Dermatitis
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
200
Alabama, Arkansas, California, Florida, Illinois, Indiana, Michigan, New York
2025-11-24
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Arizona, California, Florida, Maryland, Michigan, Minnesota, Ohio, Rhode Island
2025-11-24
Recruiting
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462Fragile X Syndrome
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419Diabetic Peripheral Neuropathic Pain
DrugSuzetrigine
Vertex Pharmaceuticals Incorporated
Phase 3
734
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-11-21
Recruiting
Generative AI Plan for Care Lab Study
NCT07552311Primary Health Care
Fitbit LLC
Not applicable
40,000
California
2025-11-21
Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRฮฑ)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT06890338Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
DrugsMirvetuximab Soravtansine·Carboplatin·Bevacizumab
AbbVie
Phase 2
140
Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana
2025-11-21
Recruiting
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
NCT06971939Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Recruiting
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
DrugDarolutamide
K36 Therapeutics, Inc.
Phase 1
144
California, Florida, Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2025-11-21
Recruiting
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
NCT07241039Advanced Squamous Tumors
DrugBudigalimab
AbbVie
Phase 1
220
California, Illinois, Michigan, North Carolina, Texas
2025-11-20
Active, closed
Efficacy and Safety of NVX-CoV2705
NCT07086222COVID-19, Sars-CoV-2 Infection
Novavax
Phase 4
6,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-11-20
Recruiting
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027Atopic Dermatitis, Eczema, Atopic
DrugPF-08049820
Pfizer
Phase 2
165
Arizona, California, Florida, New York, Pennsylvania
2025-11-20
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Phase 2
26
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-11-19
Recruiting
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
NCT07291232Obesity
DrugABBV-295
AbbVie
Phase 1
80
California, Illinois
2025-11-19
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Arizona, California, Connecticut, Florida, Georgia, Iowa, Kentucky, Louisiana
2025-11-19
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
223
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
Recruiting
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
NCT07169279Achondroplasia
QED Therapeutics, a BridgeBio company
Phase 2
77
California, Maryland, Wisconsin
2025-11-19
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
NCT07144345Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
160
California, Florida, Illinois, Indiana, Minnesota, Missouri, Oregon, South Carolina
2025-11-19
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivoยฎ, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448Colorectal Cancer
DrugsONO-4578·Opdivo·Leucovorin·Oxaliplatin
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
DrugsLeucovorin·Oxaliplatin·Bevacizumab
Summit Therapeutics
Phase 3
600
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-18
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.
Phase 1/2
27
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Pennsylvania
2025-11-18
Recruiting
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
NCT07838740Obese Adults
Viking Therapeutics, Inc.
Phase 1
270
California, Florida
2025-11-18
Active, closed
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
250
California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2025-11-17
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
DrugPembrolizumab
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Alabama, California, Florida, Michigan, Ohio, Oklahoma
2025-11-14
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-11-14
Recruiting
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.
Phase 2
153
Alabama, California, Colorado, Florida, Massachusetts, Mississippi, Missouri, Nebraska
2025-11-14
Recruiting
Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
NCT07090005Obesity, Overweight
Nitinotes Surgical Ltd.
Not applicable
184
California, New York
2025-11-14
By invitation
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07095465Lewy Body Dementia Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 3
126
California, Florida, Hawaii, Kansas, New York, Ohio, Oklahoma, Texas
2025-11-14
Recruiting
A Study to Assess Anktiva in Patients With Long Covid-19.
NCT07108036Long COVID
ImmunityBio, Inc.
Phase 2
20
California
2025-11-14
Recruiting
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
NCT07006831Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function
Devyser Inc.
Observational
400
California, Georgia, Maryland, Massachusetts, Utah
2025-11-14
Active, closed
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886Multiple Sclerosis
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
Active, closed
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390Hidradenitis Suppurativa
DrugRitlecitinib
Pfizer
Phase 2
128
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-11-13
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
NCT07223138Arthritis, Psoriatic
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
1,560
Arizona, Arkansas, California, Florida, North Carolina, Ohio, Pennsylvania, Tennessee
2025-11-13
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
DrugsFludarabine·Cyclophosphamide
Allogene Therapeutics
Phase 1
66
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky
2025-11-13
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845Ovarian Cancer
DrugsMirvetuximab Soravtansine·Carboplatin·Bevacizumab
AbbVie
Phase 2
400
California, Florida, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Montana
2025-11-13
Recruiting
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07229313Advance Solid Tumors
Kivu Bioscience Inc.
Phase 1
76
California, Connecticut
2025-11-13
Recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
800
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Recruiting
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07281079Phelan-McDermid Syndrome
DrugNNZ-2591
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 2
160
Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky
2025-11-12
Recruiting
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
83
California, Florida, Illinois, Iowa, Tennessee, Texas
2025-11-12
Recruiting
Actinium Therapy for Late-stage Aggressive Sarcomas
NCT07156565Advanced Soft Tissue Sarcoma
Ratio Therapeutics, Inc.
Phase 1
48
California, Minnesota, New York, Ohio, Texas
2025-11-12
Active, closed
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
NCT07216482Hyperlipidemia
DrugsEnlicitide·Rosuvastatin
Merck Sharp & Dohme LLC
Phase 3
996
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2025-11-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Recruiting
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
NCT07112378Eosinophilic Esophagitis (EoE)
DrugDupilumab
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Florida, Maryland, Nevada, Pennsylvania, Texas, Utah
2025-11-10
Active, closed
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577Atopic Dermatitis
DrugGIA632
Novartis Pharmaceuticals
Phase 2
34
California, Maryland, New Jersey
2025-11-10
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
DrugAZD1613
AstraZeneca
Phase 1
40
Alabama, California, Florida, Kansas, Maryland, Minnesota, Texas
2025-11-10
Active, closed
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820Pulmonary Hypertension
Pfizer
Phase 2
42
California, New York
2025-11-10
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
Active, closed
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzoneยฎ HD Vaccine (CD388.SQ.1.08/MK-1406-007)
NCT07300085Healthy Participants
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
710
California, Maryland
2025-11-08
Recruiting
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
NCT07220876Open Angle Glaucoma (OAG)
Avisi Technologies Inc.
Not applicable
165
Arizona, California, Colorado, Ohio, Pennsylvania, Texas, Wisconsin
2025-11-07
Recruiting
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
NCT07225816Obesity
DrugsLiraglutide·Semaglutide
Novo Nordisk A/S
Phase 1
71
California
2025-11-07
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Recruiting
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
NCT07226258Osteoarthritis Knee Pain
Saol Therapeutics Inc
Phase 3
150
California, Colorado, District of Columbia, Florida, Minnesota, North Carolina, Oklahoma, Oregon
2025-11-07
Recruiting
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)
NCT07216872Alcohol Use Disorder, Alcoholism, Alcohol Abuse, Alcohol Dependence
Brainsway
Not applicable
186
Alabama, California, Florida, Illinois, New York, Ohio, Oregon, West Virginia
2025-11-07
Active, closed
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
NCT07187115Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Boston Scientific Corporation
Not applicable
699
Arkansas, California, Georgia, Idaho, New York, Ohio, Pennsylvania, Texas
2025-11-07
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
DrugBrivekimig
Sanofi
Phase 2
208
Arizona, California, Florida, Georgia, Iowa, Louisiana, Missouri, Nevada
2025-11-06
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Not yet open
Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis
NCT06750588Alcohol-Associated Hepatitis
Nterica Bio inc
Phase 1
12
California
2025-11-05
Recruiting
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelxยฎ (Bimekizumab)
NCT06888193Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 1
20
California, Florida, Massachusetts, North Carolina, Wisconsin
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642Obesity, Overweight
DrugCagrilintide
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759Overweight, Obesity, Type 2 Diabetes
DrugCagrilintide
Novo Nordisk A/S
Phase 3
330
Alabama, Arizona, California, Florida, Hawaii, Indiana, Nevada, New York
2025-11-05
Recruiting
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT07219511Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
Vasa Therapeutics
Phase 1
42
Arkansas, California, Florida, Illinois, Louisiana, Missouri, New Jersey, New York
2025-11-04
Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Artivion Inc.
Not applicable
132
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-11-04
Rows per page Showing 1001–1100 of 5301
Previous 9 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california?page=11

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,301 of those studies with a site in California.

How many clinical trials are recruiting in California?

2,761 of the 5,301 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 162 have not yet opened recruitment, 2,210 are active but closed to new participants, and 168 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.